Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.

Kosuke TakemuraVishal NavaniMatthew S ErnstJ Connor WellsLuis MezaSumanta K PalJae-Lyun LeeHaoran LiNeeraj AgarwalAjjai S AlvaAaron R HansenNaveen S BasappaBernadett SzabadosThomas PowlesBen TranChristopher M HockingBenoit BeuselinckTakeshi YuasaToni K ChoueiriDaniel Y C Heng

Published in: The Journal of urology (2022)

The complete response rate was not as high in the real-world population as in the clinical trial population. Among those who experienced complete response, several adverse clinicopathological features were more frequently observed in the immuno-oncology-based cohort than in the tyrosine kinase inhibitor cohort. Complete response was an indicator of favorable overall survival.

Keyphrases

metastatic renal cell carcinoma
clinical trial
palliative care
adverse drug
open label
randomized controlled trial
emergency department
phase ii
double blind